Long Non-coding RNAs Including IRF1-AS1, LINC01871, TRG-AS1, and USP30-AS as Tumor Suppressors in Colorectal Cancer: In Silico Analysis
Archives of Advances in Biosciences,
Vol. 14 No. 1 (2023),
19 February 2023
,
Page 1-7
https://doi.org/10.22037/aab.v14i1.39529
Abstract
Introduction: Colorectal cancer (CRC) is one of the most frequently diagnosed malignancies in the world with a high mortality rate, making screening and early detection of the condition essential. Long non-coding RNAs (lncRNAs) have a significant role in the initiation and advancement of numerous malignancies, including CRC, by taking part in the control of gene and protein expression that affects apoptosis, cell proliferation, and immunological responses. In this study, through bioinformatics methods, we investigated this non-coding group in CRC and the normal group in both early and advanced stages of the disease.
Materials and Methods: In order to identify the lncRNAs that could have a tumor-suppressing role in CRC, RNA sequencing data from the cancer genome atlas (TCGA) were analyzed. Then, the Pearson correlation test was applied between the expression level of candidate lncRNAs and all genes expressed for identifying potential pathway. Genes with the highest correlation were selected and subjected to gene enrichment analysis. Also, the roles of identified lncRNAs were evaluated in terms of biomarkers.
Results: The results of the expression analysis for the TCGA data showed that the expression of the IRF1-AS1, LINC01871, TRG-AS1, and USP30-AS decreased during the progression (stages III and IV compared with stages I and II) of CRC. The enrichment results of all the genes in the co-expression network related to IRF1-AS1, LINC01871, TRG-AS1, and USP30-AS showed that these lncRNAs could play a role in immune response, inflammation, and IL-6/JAK/STAT3 signaling and apoptosis pathways. Additionally, our findings demonstrated that the aforesaid lncRNAs were significantly lower in CRC samples compared with normal samples based on TCGA data, Also, the expression of some of them may serve as an appropriate biomarker.
Conclusion: The results of this study showed that IRF1-AS1, LINC01871, TRG-AS1, and USP30-AS decreased during the progression of CRC and could play a tumor-suppressing role.
- Biomarkers
- Colorectal cancer
- Long non coding RNAs
- Immune response
How to Cite
References
Nie H, Wang Y, Liao Z, Zhou J, Ou C. The function and mechanism of circular RNAs in gastrointestinal tumours. Cell Prolif. 2020; 53(7):12815. [DOI:10.1111/cpr.12815] [PMID]
Jin Y, Yu L, Zhang B, Liu C, Chen Y. Circular RNA hsa_circ_0000523 regulates the proliferation and apoptosis of colorectal cancer cells as miRNA sponge. Braz J Med Biol Res. 2018; 51:7811. [DOI:10.1590/1414-431X20187811] [PMID] [PMCID]
Siddiqui H, Al-Ghafari A, Choudhry H, Al Doghaither H. Roles of long non-coding RNAs in colorectal cancer tumorigenesis: A Review.
Mol Clin Oncol. 2019; 11(2):167-72. [DOI:10.3892/mco.2019.1872] [PMID] [PMCID]
El Zoghbi M, Cummings LC. New era of colorectal cancer screening. World J Gastrointest Endosc. 2016; 8(5):252-8. [DOI:10.4253/wjge.v8.
i5.252] [PMID] [PMCID]
Chen T, Yang P, Wang H, He ZY. Silence of long noncoding RNA PANDAR switches low-dose curcumin-induced senescence to apoptosis in colorectal cancer cells. Onco Targets Ther. 2017; 10:483-91. [DOI:10.2147/OTT.S127547] [PMID] [PMCID]
Yousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Reza Aref A, Momeny M, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020; 39(5):953-74. [DOI:10.1038/s41388-019-1040-y] [PMID]
Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017; 15(3):177-86. [DOI: 10.1016/j.gpb.2016.12.005] [PMID] [PMCID]
Pickard MR, Williams GT. Molecular and cellular mechanisms of action of tumour suppressor GAS5 LncRNA. Genes. 2015; 6(3):484-99. [DOI:10.3390/genes6030484] [PMID] [PMCID]
Su JC, Hu XF. Long non‑coding RNA HOXA11‑AS promotes cell proliferation and metastasis in human breast cancer. Mol Med Rep. 2017; 16(4):4887-94. [DOI:10.3892/mmr.
7163] [PMID]
Huang J, Li J, Li Y, Lu Z, Che Y, Mao S, et al. Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett. 2019; 459:86-99. [DOI:10.1016/j.canlet.2019.
038] [PMID]
Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011; 17(9):2619-27. [DOI:10.1158/1078-0432.CCR-10-1114] [PMID]
Mathias C, Muzzi JCD, Antunes BB, Gradia DF, Castro MA, Carvalho de Oliveira J. Unraveling immune-related lncRNAs in breast cancer molecular subtypes. Front Oncol. 2021; 11:692170. [DOI:10.3389/fonc.2021.692170] [PMID] [PMCID]
He Y, Wang X. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
Ann Transl Med. 2020; 8(17):1050. [DOI:10.21037/atm-20-922] [PMID] [PMCID]
Chen Q, Hu L, Huang D, Chen K, Qiu X, Qiu B. Six-lncRNA immune prognostic signature for cervical cancer. Front GeneT. 2020; 11:533628. [DOI: 10.3389/fgene.2020.533628] [PMID] [PMCID]
He S, Wang X, Zhang J, Zhou F, Li L, Han X. TRG-AS1 is a potent driver of oncogenicity of tongue squamous cell carcinoma through microRNA-543/Yes-associated protein 1 axis regulation. Cell Cycle. 2020; 19(15):1969-82. [DOI:10.1080/15384101.2020.1786622] [PMID] [PMCID]
Xie H, Shi S, Chen Q, Chen Z. LncRNA TRG-AS1 promotes glioblastoma cell proliferation by competitively binding with miR-877-5p to regulate SUZ12 expression. Pathol Res Pract. 2019; 215(8):152476. [DOI:10.1016/j.prp.2019.152476] [PMID]
Sun X, Qian Y, Wang X, Cao R, Zhang J, Chen W, et al. LncRNA TRG-AS1 stimulates hepatocellular carcinoma progression by sponging miR-4500 to modulate BACH1. Cancer Cell Int. 2020; 20(1):1-11. [DOI:10.1186/s12935-020-01440-3] [PMID] [PMCID]
Zhang M, Zhu W, Haeryfar M, Jiang S, Jiang X, Chen W, et al. Long Non-Coding RNA TRG-AS1 promoted proliferation and invasion of lung cancer cells through the miR-224-5p/SMAD4 Axis. Onco Targets Ther. 2021; 14:4415-26. [DOI:10.2147/OTT.S297336] [PMID] [PMCID]
Li L, Zhang Y, Li K, Xing M, Xiao X, Zhang L, et al. Identification and validation of a novel LncRNA TRG-AS1 that inhibits colorectal
cancer proliferation and glycolysis. 2022. [DOI:10.21203/rs.3.rs-1521203/v2]
Chen M, Chi Y, Chen H, Zhao L. Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1. Oncol Lett. 2021; 22(1):1-12. [DOI:10.3892/ol.2021.12766] [PMID] [PMCID]
Wang N, Li J, Xin Q, Xu N. USP30-AS1 contributes to mitochondrial quality control in glioblastoma cells. Biochem Biophys Res Commun. 2021; 581:31-7. [DOI:10.1016/j.bbrc.2021.10.006] [PMID]
Zhou W, Xu S, Deng T, Zhou R, Wang C. LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. Hum Cell. 2022; 35(1):360-78. [DOI:10.1007/s13577-021-00636-7] [PMID] [PMCID]
Li C, Liang X, Liu Y. lncRNA USP30-AS1 sponges miR-765 and modulates the progression of colon cancer. World J Surg Oncol. 2022; 20(1):1-7. [DOI:10.1186/s12957-022-02529-x] [PMID] [PMCID]
- Abstract Viewed: 117 times
- PDF Downloaded: 64 times